Ongoing treatment(s)-Hormonal therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Looking for patients with breast cancer on hormonal therapy to trial a new drug for vasomotor symptoms

Posted by on Jun 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of Q-122, an experimental drug to treat hot flashes in breast cancer (BC). The main outcome will be the hot flash severity score (HFSS). This trial is recruiting in the United States and Australia. The details Breast cancer (BC) is one of the most common cancers in women....

Read More

Abiraterone acetate plus prednisone: an evaluation of the long-term effectiveness in prostate cancer treated with hormonal therapy.

Posted by on May 18, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients. Some background...

Read More

Looking for patients with estrogen receptor-positive breast cancer to test a new treatment combination

Posted by on May 11, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...

Read More

What is the optimal timing of exercise therapy for men taking androgen deprivation therapy?

Posted by on Jan 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the timing of exercise therapy in patients with prostate cancer taking androgen deprivation therapy (ADT). This study found that starting exercise at the onset of ADT helps preserve muscle mass and bone density.  Some background Androgen deprivation therapy (ADT) is a treatment option in...

Read More

Long term results discussing radiotherapy and hormone therapy treatments for patients with prostate cancer

Posted by on Dec 16, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...

Read More

Searching for patients with castration resistant metastatic prostate cancer to test cabazitaxel and abiraterone

Posted by on Dec 10, 2018 in Prostate cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...

Read More

Apalutamide does not affect health-related quality of life in patients with localized prostate cancer

Posted by on Nov 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on health-related quality of life (H-QoL) in patients with prostate cancer. This study found that apalutimide preserved H-QoL while prolonging time taken for cancer to spread.  Some background One treatment option for patients with prostate cancer is androgen...

Read More

Evaluating optimal duration of androgen deprivation therapy in high risk prostate cancer

Posted by on Nov 25, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients.  Some background...

Read More

Comparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer

Posted by on Nov 17, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...

Read More

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

Posted by on Oct 22, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...

Read More